文献速递细菌感染、耐药与抗菌药物医院感染防控

2015年美国新发感染计划监测点的碳青霉烯耐药铜绿假单胞菌

Carbapenem-Resistant Pseudomonas aeruginosa at US Emerging Infections Program Sites, 2015.
PubMed 文献 · Emerg Infect Dis · 2019-01-01

Pseudomonas aeruginosa is intrinsically resistant to many antimicrobial drugs, making carbapenems crucial in clinical management. During July-October 2015 in the United States, we piloted laboratory-based surveillance for carbapenem-resistant P.…

要点

  • CRPA负担在监测机构中较高,但产碳青霉烯酶CRPA罕见。
  • 多数CRPA病例发生于既往一年有住院史的患者。
  • 呼吸道和尿液是CRPA最常见分离部位。

核心结论

  • 监测机构中CRPA负担较高,但产碳青霉烯酶CRPA罕见。

研究设计与样本

  • incident 病例定义为患者30天内首次分离出对多种抗铜绿假单胞菌碳青霉烯类耐药的铜绿假单胞菌,标本来源排除鼻孔、直肠或肛周区域及粪便。

主要发现

  • 共发现274例患者的294例 incident 病例。
  • 病例最常见分离自呼吸道部位(120/294;40.8%)和尿液(111/294;37.8%)。
  • 多数病例(223/280;79.6%)发生于既往一年有医疗机构住院史的患者。
  • 129株受检分离株中,3株(2.3%)检出编码碳青霉烯酶的基因。

临床怎么用

  • 在监测机构中应关注CRPA的较高负担,尤其是有近期住院史的患者。
  • 产碳青霉烯酶CRPA虽罕见,但仍需实验室监测以识别。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pseudomonas aeruginosa is intrinsically resistant to many antimicrobial drugs, making carbapenems crucial in clinical management. During July-October 2015 in the United States, we piloted laboratory-based surveillance for carbapenem-resistant P. aeruginosa (CRPA) at sentinel facilities in Georgia, New Mexico, Oregon, and Tennessee, and population-based surveillance in Monroe County, NY. An incident case was the first P. aeruginosa isolate resistant to antipseudomonal carbapenems from a patient in a 30-day period from any source except the nares, rectum or perirectal area, or feces. We found 294 incident cases among 274 patients. Cases were most commonly identified from respiratory sites (120/294; 40.8%) and urine (111/294; 37.8%); most (223/280; 79.6%) occurred in patients with healthcare facility inpatient stays in the prior year. Genes encoding carbapenemases were identified in 3 (2.3%) of 129 isolates tested. The burden of CRPA was high at facilities under surveillance, but carbapenemase-producing CRPA were rare.

来源:Emerg Infect Dis,查看原文。版权归原作者所有。

引用

  1. Walters MS, Grass JE, Bulens SN, et al. Carbapenem-Resistant Pseudomonas aeruginosa at US Emerging Infections Program Sites, 2015. Emerg Infect Dis. 2019. PMID: 31211681. doi:10.3201/eid2507.181200

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。